95344-18-6

Upstream product

• 83967-03-7 C-IDU 
• 292638-85-8 acrylic acid methyl ester 
• 59967-83-8 (+/-)-1-<(1β,2α,3α,4β)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl>-2,4-(1H,3H)-pyrimidinedione 

Downstream Products

• 95313-04-5 (+/-)-1-<(1α,3β,4α)-3-hydroxy-4-(hydroxymethyl)cyclopentyl>-4-amino-5-<(E)-2-bromovinyl>-2(1H)-pyrimidinone 
• 91661-22-2 (+/-)-1-<(1α,3β,4α)-3-hydroxy-4-(hydroxymethyl)cyclopentyl>-5-<(E)-2-bromovinyl>-2,4(1H,3H)-pyrimidinedione 
• 91661-22-2 5-((E)-2-Bromo-vinyl)-1-((1S,3S,4S)-3-hydroxy-4-hydroxymethyl-cyclopentyl)-1H-pyrimidine-2,4-dione 

Relevant academic research and scientific papers

Synthesis and Antiviral Activity of the Carbocyclic Analogues of (E)-5-(2-Halovinyl)-2'-deoxyuridines and (E)-5-(2-Halovinyl)-2'-deoxycytidines

The carbocyclic analogues of the potent and selective antiherpes agents (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU), and (E)-5-(2-bromovinyl)-2'-deoxycytidine (BVDC) were synthesized by conventional methods with use of carbocyclic 2'-deoxyuridine as starting material.C-BVDU, C-IVDU, and C-BVDC were equally selective, albeit slightly less potent, in their antiherpes action than BVDU, IVDU, and BVDC.Although resistant to degradation by pyrimidine nucleoside phosphorylases, C-BVDU did not prove more effective than BVDU in the systemic (oral, intraperitoneal) or topical treatment of HSV-1 infections in mice.